For the eighth consecutive year, AstraZeneca has received the prestigious CEO Cancer Gold Standard™ accreditation. This status recognizes a company’s significant commitment to helping employees and their families with cancer prevention, early detection and access to quality care.
As one of the first six companies to receive this accreditation in 2006, AstraZeneca is fully committed to providing a healthy workplace to our employees. Some examples of workplace programs include on-site fitness centers and walking/running paths, nutritious options in cafeterias and vending machines and on-site breast, prostate and skin cancer screenings.
In the past 20 years, more than 12,000 mammograms were performed on-site at AstraZeneca and 49 malignancies identified in early stages that allowed for successful treatment outcomes. In 1989, AstraZeneca purchased its first x-ray mammography system to screen its employees. In 2013, the company purchased a leading-edge digital mammography system to provide its people the most advanced breast cancer screening technology available.
AstraZeneca’s 2013 reaccreditation is based on our ongoing promotion of employee cancer-prevention initiatives and our “remarkable dedication and commitment to maintaining this high standard of excellence,” notes Dr. Martin J. Murphy, convener & CEO of the CEO Roundtable on Cancer.
The Gold Standard was created by The CEO Roundtable on Cancer, a nonprofit organization founded in 2001 by cancer-fighter CEOs in response to the former President George H. W. Bush’s challenge that they be “bold and venturesome” in the fight against this disease.
To learn more, visit the CEO Cancer Gold Standard website.